302 related articles for article (PubMed ID: 21753154)
1. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors.
Lorusso PM; Jimeno A; Dy G; Adjei A; Berlin J; Leichman L; Low JA; Colburn D; Chang I; Cheeti S; Jin JY; Graham RA
Clin Cancer Res; 2011 Sep; 17(17):5774-82. PubMed ID: 21753154
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding.
Graham RA; Lum BL; Cheeti S; Jin JY; Jorga K; Von Hoff DD; Rudin CM; Reddy JC; Low JA; Lorusso PM
Clin Cancer Res; 2011 Apr; 17(8):2512-20. PubMed ID: 21300760
[TBL] [Abstract][Full Text] [Related]
3. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
[TBL] [Abstract][Full Text] [Related]
4. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
5. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H; Alicke B; West KA; Pacheco P; La H; Januario T; Yauch RL; de Sauvage FJ; Gould SE
Clin Cancer Res; 2011 Jul; 17(14):4682-92. PubMed ID: 21610148
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
Abou-Alfa GK; Lewis LD; LoRusso P; Maitland M; Chandra P; Cheeti S; Colburn D; Williams S; Simmons B; Graham RA
Cancer Chemother Pharmacol; 2017 Jul; 80(1):29-36. PubMed ID: 28523596
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
9. Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects.
Graham RA; Hop CE; Borin MT; Lum BL; Colburn D; Chang I; Shin YG; Malhi V; Low JA; Dresser MJ
Br J Clin Pharmacol; 2012 Nov; 74(5):788-96. PubMed ID: 22458643
[TBL] [Abstract][Full Text] [Related]
10. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
11. Daily dosing of vismodegib to steady state does not prolong the QTc interval in healthy volunteers.
Graham RA; Chang I; Jin JY; Wang B; Dufek MB; Ayache JA; Ezzet F; Zerivitz K; Low JA; Dresser MJ
J Cardiovasc Pharmacol; 2013 Jan; 61(1):83-9. PubMed ID: 23107871
[TBL] [Abstract][Full Text] [Related]
12. Identification, characterization, and implications of species-dependent plasma protein binding for the oral Hedgehog pathway inhibitor vismodegib (GDC-0449).
Giannetti AM; Wong H; Dijkgraaf GJ; Dueber EC; Ortwine DF; Bravo BJ; Gould SE; Plise EG; Lum BL; Malhi V; Graham RA
J Med Chem; 2011 Apr; 54(8):2592-601. PubMed ID: 21438527
[TBL] [Abstract][Full Text] [Related]
13. Determination of unbound vismodegib (GDC-0449) concentration in human plasma using rapid equilibrium dialysis followed by solid phase extraction and high-performance liquid chromatography coupled to mass spectrometry.
Deng Y; Wong H; Graham RA; Liu W; Shen HS; Shi Y; Wang L; Meng M; Malhi V; Ding X; Dean B
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Jul; 879(22):2119-26. PubMed ID: 21704573
[TBL] [Abstract][Full Text] [Related]
14. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
Dirix L; Rutten A
Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
Sharma MR; Karrison TG; Kell B; Wu K; Turcich M; Geary D; Kang SP; Takebe N; Graham RA; Maitland ML; Schilsky RL; Ratain MJ; Cohen EE
Clin Cancer Res; 2013 Jun; 19(11):3059-67. PubMed ID: 23553850
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.
LoRusso PM; Rudin CM; Reddy JC; Tibes R; Weiss GJ; Borad MJ; Hann CL; Brahmer JR; Chang I; Darbonne WC; Graham RA; Zerivitz KL; Low JA; Von Hoff DD
Clin Cancer Res; 2011 Apr; 17(8):2502-11. PubMed ID: 21300762
[TBL] [Abstract][Full Text] [Related]
17. Absorption, distribution, metabolism, and excretion of [¹⁴C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening.
Yue Q; Chen YH; Mulder T; Deese A; Takahashi R; Rudewicz PJ; Reynolds M; Solon E; Hop CE; Wong H; Khojasteh SC
Drug Metab Dispos; 2011 Jun; 39(6):952-65. PubMed ID: 21363998
[TBL] [Abstract][Full Text] [Related]
18. Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential.
LoRusso PM; Piha-Paul SA; Mita M; Colevas AD; Malhi V; Colburn D; Yin M; Low JA; Graham RA
Cancer Chemother Pharmacol; 2013 Jan; 71(1):193-202. PubMed ID: 23064958
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers.
De Smaele E; Ferretti E; Gulino A
Curr Opin Investig Drugs; 2010 Jun; 11(6):707-18. PubMed ID: 20496266
[TBL] [Abstract][Full Text] [Related]
20. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
